LINE241220P50000
- 0.00
- 0.000.00%
Lineage Newsroom
BRIDGETOWER CAPITAL LAUNCHES SOVEREIGN AI DATA LINEAGE SOLUTION AND PARTNERS WITH, INTERVISION SYSTEMS, AND PROVLABS - FACILITATOR OF $41B OF FINANCIAL TRANSACTIONS - TO AUTHENTICATE AI DATA GLOBALLY
Lineage To Go Ex-Dividend On December 31st, 2024 With 0.5275 USD Dividend Per Share
Lineage Declares Dividend of $0.5275 >LINE
Press Release: Lineage, Inc. Declares Dividend for Fourth Quarter 2024
Scotiabank Maintains Lineage(LINE.US) With Buy Rating, Cuts Target Price to $76
A Closer Look at 8 Analyst Recommendations For Lineage
Lineage Is Maintained at Sector Outperform by Scotiabank
Express News | Lineage Inc : Scotiabank Cuts Target Price to $76 From $94
Evercore Maintains Lineage(LINE.US) With Hold Rating, Cuts Target Price to $73
Lineage, Inc. (LINE) Receives a Hold From Evercore ISI
Rabobank Honors Lineage at Annual Leadership Summit
Lineage Cell Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Lineage Cell Therapeutics Inc : H.c. Wainwright Raises Target Price to $9 From $7
Ryp Labs Crowned the Winner of Lineage's 2024 Global Food Chain Innovation Challenge
Is Lineage Cell Therapeutics (LCTX) the Best New Pick in Brad Gerstner's Portfolio?
J.P. Morgan Remains a Buy on Lineage, Inc. (LINE)
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
Lineage Explores Connection Between Food Infrastructure and Economic Development in New Research by Economist Impact
Lineage Cell Price Target Lowered to $2 From $3 at D. Boral Capital
Lineage Cell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of up to a $66 Million Registered Direct Offering. Also, D Boral Capital Maintained a Buy Rating on the Stock and Lowered Its Price Target From $3 to $2.